APTOSE BIOSCIENCES INC (APS.CA) Stock Fundamental Analysis
Canada - TSX:APS - CA03835T4081 - Common Stock
2.34 CAD
-0.02 (-0.85%)
Taking everything into account, APS scores 1 out of 10 in our fundamental rating. APS was compared to 21 industry peers in the Biotechnology industry. APS may be in some trouble as it scores bad on both profitability and health. APS is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
APS had negative earnings in the past year.
In the past year APS has reported a negative cash flow from operations.
APS had negative earnings in each of the past 5 years.
In the past 5 years APS always reported negative operating cash flow.
1.2 Ratios
APS has a worse Return On Assets (-327.57%) than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.57% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for APS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
There is no outstanding debt for APS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
APS has an Altman-Z score of -79.84. This is a bad value and indicates that APS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -79.84, APS is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -79.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
APS has a Current Ratio of 1.05. This is a normal value and indicates that APS is financially healthy and should not expect problems in meeting its short term obligations.
APS has a Current ratio of 1.05. This is comparable to the rest of the industry: APS outperforms 42.86% of its industry peers.
APS has a Quick Ratio of 1.05. This is a normal value and indicates that APS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.05, APS perfoms like the industry average, outperforming 47.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
APS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.60%, which is quite impressive.
EPS 1Y (TTM)79.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 16.16% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.27%
EPS Next 2Y40.08%
EPS Next 3Y26.19%
EPS Next 5Y16.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
APS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
APS's earnings are expected to grow with 26.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.08%
EPS Next 3Y26.19%
5. Dividend
5.1 Amount
No dividends for APS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:APS (11/20/2025, 7:00:00 PM)
2.34
-0.02 (-0.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.99%
Inst Owner ChangeN/A
Ins Owners0.32%
Ins Owner ChangeN/A
Market Cap5.97M
Revenue(TTM)N/A
Net Income(TTM)-35.80M
Analysts82.86
Price Target136.76 (5744.44%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)66.9%
Min EPS beat(2)64.27%
Max EPS beat(2)69.52%
EPS beat(4)4
Avg EPS beat(4)37.14%
Min EPS beat(4)3.29%
Max EPS beat(4)69.52%
EPS beat(8)6
Avg EPS beat(8)16.09%
EPS beat(12)9
Avg EPS beat(12)10.77%
EPS beat(16)12
Avg EPS beat(16)11.13%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-66.19
EYN/A
EPS(NY)-3.13
Fwd EYN/A
FCF(TTM)-20.43
FCFYN/A
OCF(TTM)-20.43
OCFYN/A
SpS0
BVpS-5.02
TBVpS-5.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -327.57% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-185.13%
ROA(5y)-125.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z | -79.84 |
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.76%
Cap/Depr(5y)62.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.91%
EPS Next Y95.27%
EPS Next 2Y40.08%
EPS Next 3Y26.19%
EPS Next 5Y16.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.1%
EBIT Next 3Y11.61%
EBIT Next 5YN/A
FCF growth 1Y6.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.39%
OCF growth 3YN/A
OCF growth 5YN/A
APTOSE BIOSCIENCES INC / APS.CA FAQ
What is the ChartMill fundamental rating of APTOSE BIOSCIENCES INC (APS.CA) stock?
ChartMill assigns a fundamental rating of 1 / 10 to APS.CA.
What is the valuation status for APS stock?
ChartMill assigns a valuation rating of 1 / 10 to APTOSE BIOSCIENCES INC (APS.CA). This can be considered as Overvalued.
Can you provide the profitability details for APTOSE BIOSCIENCES INC?
APTOSE BIOSCIENCES INC (APS.CA) has a profitability rating of 0 / 10.